Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal

In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to acquire Zenas shares up to 15% of Zenas’ equity.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.